Skip to main content

Bacillus coagulans GBI-30, 6086 Modulates Faecalibacterium prausnitzii in Older Men and Women.

  • 2015-07
  • The Journal of Nutrition 145(7)
    • Edna P Nyangale
    • S. Farmer
    • H. Cash
    • D. Keller
    • D. Chernoff
    • G. Gibson

Abstract

Background: Advancing age is linked to a decrease in beneficial bacteria such as Bifidobacterium spp. and reduced aspects of innate immune function.

Objectives: We investigated whether daily consumption of a probiotic [Bacillus coagulans GBI-30, 6086 (BC30); GanedenBC(30)] could improve immune function and gut function in men and women aged 65-80 y, using a double-blind, placebo-controlled crossover design.

Method: Thirty-six volunteers were recruited and randomly assigned to receive either a placebo (microcrystalline cellulose) or the probiotic BC30 (1 × 10(9) colony-forming units/capsule). Volunteers consumed 1 treatment capsule per day for 28 d, followed by a 21-d washout period before switching to the other treatment. Blood and fecal samples were collected at the beginning and end of each treatment period. Fecal samples were used to enumerate bacterial groups and concentrations of calprotectin. Peripheral blood mononuclear cells (PBMCs) were extracted from whole blood to assess natural killer cell activity and lipopolysaccharide (LPS)-stimulated cytokine production. C-reactive protein concentrations were measured in plasma.

Results: Consumption of BC30 significantly increased populations of Faecalibacterium prausnitzii by 0.1 log10 cells/mL more than during consumption of the placebo (P = 0.03), whereas populations of Bacillus spp. increased significantly by 0.5 log10 cells/mL from baseline in volunteers who consumed BC30 (P = 0.007). LPS-stimulated PBMCs showed a 0.2 ng/mL increase in the anti-inflammatory cytokine IL-10 28 d after consumption of BC30 (P < 0.05), whereas the placebo did not affect IL-10, and no overall difference was found in the effect of the treatments.

Conclusions: Daily consumption of BC30 by adults aged 65-80 y can increase beneficial groups of bacteria in the human gut and potentially increase production of anti-inflammatory cytokines. This study shows the potential benefits of a probiotic to improve dysbiosis via modulation of the microbiota in older persons.

Keywords: BC30; Bacillus coagulans; Faecalibacterium prausnitzii; interleukin-10; probiotic.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bacillus coagulansIncreased Bacillus Species PopulationsBeneficial
Moderate
Bacillus coagulansIncreased Faecalibacterium prausnitzii PopulationBeneficial
Small
Bacillus coagulansIncreased IL-10 Anti-Inflammatory Cytokine ProductionBeneficial
Small
Bacillus coagulans GBI-30, 6086Increased Bacillus Species PopulationsBeneficial
Moderate
Bacillus coagulans GBI-30, 6086Increased IL-10 ProductionBeneficial
Small
Bacillus coagulans ProDuraIncreased Bacillus SpeciesBeneficial
Moderate
Bacillus coagulans ProDuraIncreased Faecalibacterium prausnitzii LevelsBeneficial
Small
Bacillus coagulans ProDuraIncreased Production of Anti-inflammatory Cytokine IL-10Beneficial
Small
Bacillus coagulans SC208Increased Bacillus Species PopulationsBeneficial
Moderate
Bacillus coagulans SC208Increased Faecalibacterium prausnitzii LevelsBeneficial
Small
Bacillus coagulans SC208Increased IL-10 ProductionBeneficial
Small
Bacillus coagulans SNZ-1969Increased Bacillus SpeciesBeneficial
Moderate
Bacillus coagulans SNZ-1969Increased Faecalibacterium prausnitzii LevelsBeneficial
Small
Bacillus coagulans SNZ-1969Increased IL-10 ProductionBeneficial
Small

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.